Skip to main content

Bio-Rad, Layerlab Collaboration Enables Research into Kinetics of Transmembrane Proteins


This story originally ran on April 22.

Bio-Rad Laboratories and Layerlab earlier this month announced a partnership utilizing each others' technologies for the study of binding kinetics of transmembrane proteins.

Under the collaboration, whose terms were not disclosed, the two firms will test and validate the use of Layerlab's technology on Bio-Rad's ProteOn XPR36 multiplexed surface plasmon resonance biosensor.

In addition, the work will involve lipoparticle technology from Integral Molecular, Laura Moriarty, product manager in the Protein Function Division of Bio-Rad, told ProteoMonitor in an e-mail.

In a statement, Bio-Rad said that by using Layerlab's novel methodology and memLayer chemistry kit, researchers can "easily immobilize liposomes containing transmembrane proteins to the ProteOn XPR36 system biosensor chip surfaces for label-free high-throughput kinetic analysis with high signal quality."

"Examining transmembrane proteins in liposomes, as opposed to isolated and bound to a sensor surface, enables researchers to mimic the cellular environment and preserve protein functionality," Bio-Rad added.

The memLayer tag is spontaneously incorporated into any liposome membrane, which allows for the kinetic analysis of transmembrane proteins in liposomes "that cannot be immobilized by standard techniques such as biotin-neutravidin derivitization," the company said.

Based in Göteborg, Sweden, Layerlab develops biosensors, tools for membrane surface research, and other specialized technologies. According to Bio-Rad, Layerlab's lipid bilayer immobilization method allows researchers to achieve densities of membrane-bound receptor molecules that previously had been impossible.

The method, Bio-Rad added, allows for continual regeneration of biosensor surfaces, prolonging the life and use of Bio-Rad sensor chips.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.